Ujike H, Morita Y: New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004; 96:376-381
Travis MJ, Burns T, Dursun S, et al: Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005; 59:485-495
Beresford TP, et al: Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005; 25:363-366
Pilla M, et al: Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999; 400:371-375
Kenna GA, McGeary JE, Swift RM: Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 2. Am J Health Syst Pharm 2004; 61:2380-2388
Kenna GA: Rationale for use of aripiprazole for alcohol dependence treatment. Drugs Future 2003; 28:1227-1235
Warsi M, et al: Aripiprazole reduces alcohol use. Can J Psychiatry 2005; 50:244
McEvoy JP, et al: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995; 119:124-126
